BT-20 (Bone Therapeutics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameBT-20 (Bone Therapeutics)
Drug Alias Nameallogeneic bone marrow-derived mesenchymal stromal cell therapy (Bone Therapeutics)BT-20 (BioSenic)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionImmunomodulators
TargetsUpdating
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)InflammationRespiratory Distress Syndrome, Adult
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgium
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBiosenic SA
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiosenic SA
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)InflammationRespiratory Distress Syndrome, Adult

Other Information

ATC CodeN/A
Related LinksN/A